Abbott Labs (ABT) stock price target cut to $120 by Benchmark
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowBenchmark has reduced its price target for Abbott Labs (ABT) stock to $120. This change reflects a re-evaluation of the company's valuation metrics. Such a downgrade can influence market perceptions and potentially impact stock performance. It is essential to monitor how this adjustment affects trading volume and investor sentiment moving forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABT news
- Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
- Abbott (ABT) Jury Orders $53 Million Payment in Formula Case
- Abbott Laboratories Completes Acquisition of Exact Sciences, Strengthens Market Position
- Abbott Laboratories Q3 Earnings Report Shows $1.15 Earnings Per Share
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
